DK2388317T3 - Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom - Google Patents

Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom

Info

Publication number
DK2388317T3
DK2388317T3 DK10729101.5T DK10729101T DK2388317T3 DK 2388317 T3 DK2388317 T3 DK 2388317T3 DK 10729101 T DK10729101 T DK 10729101T DK 2388317 T3 DK2388317 T3 DK 2388317T3
Authority
DK
Denmark
Prior art keywords
disease
prevention
treatment
gene encoding
human glucokinase
Prior art date
Application number
DK10729101.5T
Other languages
English (en)
Inventor
Haidong Huang
Original Assignee
Yiyuan (Shenzhen) Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yiyuan (Shenzhen) Biotech Ltd filed Critical Yiyuan (Shenzhen) Biotech Ltd
Application granted granted Critical
Publication of DK2388317T3 publication Critical patent/DK2388317T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10729101.5T 2009-01-07 2010-01-06 Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom DK2388317T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910000087 2009-01-07
PCT/CN2010/070038 WO2010078842A1 (zh) 2009-01-07 2010-01-06 人葡萄糖激酶突变体编码基因、其编码的酶、重组载体及宿主、其药物组合物、应用以及预防和治疗疾病的方法

Publications (1)

Publication Number Publication Date
DK2388317T3 true DK2388317T3 (da) 2017-11-27

Family

ID=42316263

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10729101.5T DK2388317T3 (da) 2009-01-07 2010-01-06 Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom

Country Status (21)

Country Link
US (1) US9029142B2 (da)
EP (1) EP2388317B1 (da)
JP (1) JP5721637B2 (da)
KR (1) KR101300540B1 (da)
CN (1) CN102272296B (da)
AP (1) AP3277A (da)
AU (1) AU2010204379B2 (da)
BR (1) BRPI1006104B8 (da)
CA (1) CA2749180C (da)
DK (1) DK2388317T3 (da)
EA (1) EA024878B1 (da)
ES (1) ES2649021T3 (da)
HU (1) HUE035110T2 (da)
IL (1) IL213750A (da)
MA (1) MA33034B1 (da)
MX (1) MX2011007263A (da)
NZ (1) NZ593893A (da)
PT (1) PT2388317T (da)
SG (1) SG172851A1 (da)
WO (1) WO2010078842A1 (da)
ZA (1) ZA201105209B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376528B1 (en) 2008-12-29 2014-11-26 Tel Hashomer Medical Research, Infrastructure And Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
KR101300540B1 (ko) 2009-01-07 2013-09-02 하이동 후앙 인간 글루코키나제 돌연변이체 코딩 유전자, 이에 의하여 코딩된 효소, 재조합 벡터 및 숙주, 이의 약학적 조성물 및 용도, 및 질병의 예방 및 치료 방법
WO2013117776A1 (es) * 2012-02-08 2013-08-15 Fundación Pública Andaluza Progreso Y Salud Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Aseko, Inc. Subcutaneous outpatient management
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
CN110564777B (zh) * 2019-09-23 2021-09-10 北京希诺谷生物科技有限公司 糖尿病疾病模型犬的建立方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
ES2170720B1 (es) * 2000-12-20 2003-12-16 Univ Barcelona Autonoma Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
US20070219346A1 (en) * 2002-04-22 2007-09-20 Mcgill University Glucose sensor and uses thereof
WO2005052132A2 (en) * 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
GB0423173D0 (en) * 2004-10-19 2004-11-24 Univ Newcastle Treatment of diabetes
WO2006130672A1 (en) * 2005-06-01 2006-12-07 Biotech Institute For International Innovation, Inc. Glucose inducible insulin expression and methods of treating diabetes
ES2550229T3 (es) * 2007-08-10 2015-11-05 University Of Technology, Sydney Células modificadas genéticamente para comprender glucoquinasa de islote pancreático y usos de éstas
KR101300540B1 (ko) 2009-01-07 2013-09-02 하이동 후앙 인간 글루코키나제 돌연변이체 코딩 유전자, 이에 의하여 코딩된 효소, 재조합 벡터 및 숙주, 이의 약학적 조성물 및 용도, 및 질병의 예방 및 치료 방법

Also Published As

Publication number Publication date
AP2011005814A0 (en) 2011-08-31
US9029142B2 (en) 2015-05-12
BRPI1006104B1 (pt) 2021-04-20
JP2012514463A (ja) 2012-06-28
PT2388317T (pt) 2017-11-27
AU2010204379A1 (en) 2011-07-28
SG172851A1 (en) 2011-08-29
ES2649021T3 (es) 2018-01-09
MX2011007263A (es) 2011-10-06
US20110286984A1 (en) 2011-11-24
NZ593893A (en) 2013-02-22
EP2388317B1 (en) 2017-08-30
EA201170917A1 (ru) 2011-12-30
CA2749180A1 (en) 2010-07-15
WO2010078842A1 (zh) 2010-07-15
JP5721637B2 (ja) 2015-05-20
EP2388317A1 (en) 2011-11-23
CN102272296A (zh) 2011-12-07
EP2388317A4 (en) 2012-11-28
BRPI1006104A2 (pt) 2016-02-16
EA024878B1 (ru) 2016-10-31
KR101300540B1 (ko) 2013-09-02
MA33034B1 (fr) 2012-02-01
IL213750A0 (en) 2011-07-31
KR20110099057A (ko) 2011-09-05
CN102272296B (zh) 2012-10-24
ZA201105209B (en) 2012-09-26
AU2010204379B2 (en) 2014-02-13
AP3277A (en) 2015-05-31
CA2749180C (en) 2017-03-21
HUE035110T2 (en) 2018-05-02
IL213750A (en) 2015-11-30
BRPI1006104B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
DK2388317T3 (da) Gen, som koder for en human glucokinasemutant, og anvendelser deraf til behandling eller forebyggelse af sygdom
HK1217293A1 (zh) 預防或治療心力衰竭的方法
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
AP2011005944A0 (en) Inhibitors of human immunodeficiency virus replication.
DK2808024T3 (da) Bifidobakterier til behandling af kongestiv hjerteinsufficiens
BR112012008058A2 (pt) implantes e modelos ortopédicos específicos para o paciente.
DK2047863T3 (da) Middel til forebyggelse eller behandling af inflammatoriske sygdomme
EP2349140A4 (en) DEVICES, SYSTEMS AND METHODS FOR TREATING SLEEP APNEA
DK2448637T3 (da) Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
DK2417257T3 (da) Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom
DK2479174T3 (da) 6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
EP2220046A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
WO2010083347A3 (en) Peptidomimetic macrocycles
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
EP2401264A4 (en) PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
DK2384327T3 (da) Forbindelse med kondenseret ring og anvendelse deraf.
DK2750551T3 (da) Ortopædisk stol til behandling og forebyggelse af rygmarvslidelser
DK2486334T3 (da) Fremgangsmåder og anordninger til fortrængning af kropskonvektion og tilvejebringelse af en kontrolleret, personlig vejrtrækningszone
EP2337535A4 (en) SYSTEMS, DEVICES AND METHODS FOR THE TREATMENT OF ACOUPHEN
DK2087094T3 (da) Lactobacillus fermentum ess-1, dsm17851 og dets anvendelse til behandlingen og/eller forebyggelse af candidiasis og urinvejsinfektioner
DK2432798T3 (da) 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme
BR112013015771A2 (pt) derivados de ciclosporina para o tratamento e a prevenção de uma infecção viral
BRPI1011535A2 (pt) tratamento de distúrbios resistentes à insulina.